{"disease":{"id":"glioblastoma-recurrent","name":"glioblastoma recurrent"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05902169","title":"Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":560,"lead_sponsor_name":"CarThera","has_results":false},{"nct_id":"NCT06283927","title":"The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)","phase":"","overall_status":"RECRUITING","enrollment_count":464,"lead_sponsor_name":"Jasper Gerritsen","has_results":false},{"nct_id":"NCT06273176","title":"The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma","phase":"","overall_status":"RECRUITING","enrollment_count":225,"lead_sponsor_name":"Erasmus Medical Center","has_results":false},{"nct_id":"NCT04732065","title":"ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":208,"lead_sponsor_name":"Sabine Mueller, MD, PhD","has_results":false},{"nct_id":"NCT06325683","title":"Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma","phase":"PHASE2","overall_status":"SUSPENDED","enrollment_count":184,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01730950","title":"Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":182,"lead_sponsor_name":"Radiation Therapy Oncology Group","has_results":true},{"nct_id":"NCT04044937","title":"Fluoroethyltyrosine for Evaluation of Intracranial Neoplasms","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":143,"lead_sponsor_name":"Thomas Hope","has_results":false},{"nct_id":"NCT01609790","title":"Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":137,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06160206","title":"Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":134,"lead_sponsor_name":"Academic and Community Cancer Research United","has_results":false},{"nct_id":"NCT03154190","title":"Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":128,"lead_sponsor_name":"Stanford University","has_results":true},{"nct_id":"NCT00433381","title":"Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":123,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT00329719","title":"Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":115,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04267978","title":"Study of Recombinant Human Endostatin Combined with Temozolomide and Irinotecan in Recurrent Gliomas","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":109,"lead_sponsor_name":"Beijing Sanbo Brain Hospital","has_results":false},{"nct_id":"NCT03025893","title":"A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Amsterdam UMC, location VUmc","has_results":false},{"nct_id":"NCT05432804","title":"Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment","phase":"PHASE1, PHASE2","overall_status":"SUSPENDED","enrollment_count":97,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01814813","title":"Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":90,"lead_sponsor_name":"Alliance for Clinical Trials in Oncology","has_results":true},{"nct_id":"NCT03212274","title":"Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":89,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT00268385","title":"Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":83,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05463848","title":"Surgical Pembro +/- Olaparib w TMZ for rGBM","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":78,"lead_sponsor_name":"L. Nicolas Gonzalez Castro, MD, PhD","has_results":false},{"nct_id":"NCT03749187","title":"BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":78,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT04541225","title":"Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":74,"lead_sponsor_name":"Nuvation Bio Inc.","has_results":false},{"nct_id":"NCT01849146","title":"Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":74,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04477200","title":"Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":68,"lead_sponsor_name":"University of Michigan Rogel Cancer Center","has_results":false},{"nct_id":"NCT03434262","title":"SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":68,"lead_sponsor_name":"St. Jude Children's Research Hospital","has_results":false},{"nct_id":"NCT03914742","title":"BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":67,"lead_sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","has_results":true},{"nct_id":"NCT02208362","title":"Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":65,"lead_sponsor_name":"City of Hope Medical Center","has_results":true},{"nct_id":"NCT02661282","title":"Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":65,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT03782415","title":"Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":64,"lead_sponsor_name":"MediciNova","has_results":false},{"nct_id":"NCT00423735","title":"Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":64,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02658981","title":"Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":63,"lead_sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","has_results":false},{"nct_id":"NCT05236036","title":"Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":60,"lead_sponsor_name":"Northwestern University","has_results":false},{"nct_id":"NCT02323880","title":"Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":59,"lead_sponsor_name":"Children's Oncology Group","has_results":true},{"nct_id":"NCT04528680","title":"Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":57,"lead_sponsor_name":"Northwestern University","has_results":false},{"nct_id":"NCT05465954","title":"Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":54,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT06090903","title":"Magnetic Resonance Imaging for Improving Knowledge of Brain Tumor Biology in Patients With Resectable Glioblastoma","phase":"NA","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Jonsson Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT02142803","title":"TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":50,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05557292","title":"RMC-5552 Monotherapy in Adult Subjects With Recurrent Glioblastoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":48,"lead_sponsor_name":"Nicholas Butowski","has_results":false},{"nct_id":"NCT01817751","title":"Sorafenib, Valproic Acid, and Sildenafil in Treating Patients With Recurrent High-Grade Glioma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":47,"lead_sponsor_name":"Virginia Commonwealth University","has_results":true},{"nct_id":"NCT04671459","title":"TTFields and Radiosurgery of Recurrent Glioblastoma +/- 18F-Fluoro-Ethyl-Thyrosine","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Prof. Franciszek Lukaszczyk Memorial Oncology Center","has_results":false},{"nct_id":"NCT07416188","title":"Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":40,"lead_sponsor_name":"National Institute of Neurological Disorders and Stroke (NINDS)","has_results":false},{"nct_id":"NCT05303467","title":"A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"Boston Scientific Corporation","has_results":false},{"nct_id":"NCT07480941","title":"Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"Beijing Biotech","has_results":false},{"nct_id":"NCT07301268","title":"GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03896568","title":"MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT01051557","title":"Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02255461","title":"Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":35,"lead_sponsor_name":"Pediatric Brain Tumor Consortium","has_results":true},{"nct_id":"NCT00102648","title":"Lonafarnib and Temozolomide in Treating Patients with Glioblastoma Multiforme That is Recurrent or Did Not Respond to Previous Treatment with Temozolomide","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":34,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT01753713","title":"Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":33,"lead_sponsor_name":"Manmeet Ahluwalia, MD","has_results":true},{"nct_id":"NCT03107780","title":"Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":32,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06496971","title":"A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":32,"lead_sponsor_name":"NaviFUS Corporation","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}